A $1.8 billion valuation and no human efficacy data. Here is how the math works.

Retro Biosciences, the longevity company founded with roughly $180 million from the chief executive of OpenAI and with the stated goal of adding ten years to healthy human lifespan, announced today an initial close of its next financing at a pre-money valuation of $1.8 billion, led by a firm called 4P Capital. The amount raised was not disclosed. Its lead candidate, an oral drug designed to restart the cell's recycling process, is in a Phase 1 safety trial in Australia in patients with Alzheimer's disease, with data expected around August. Six months ago, STAT reported that the company was seeking a $5 billion valuation with no clinical data yet, on a fundraising slide reading that longevity would be the greatest pharma market of all time. It got $1.8 billion. We want to show you how a number like that is built, because the same arithmetic prices everything in this industry.

The arithmetic. A valuation before data is a bet on three things multiplied together: the size of the market if the drug works, the probability it works, and the discount for how long it will take. The first number is the one on the slide — enormous, because "aging" is everyone. The second is the one nobody says out loud: for a drug entering Phase 1, history puts the chance of eventual approval in the single digits to low teens, and for a new mechanism in Alzheimer's, lower. The third is a decade. Multiply a huge market by a small probability and discount it ten years, and you get a figure that can be $5 billion or $1.8 billion depending on the mood of the people in the room — which is what happened between December and today. Nothing about the drug changed. The appetite did.

Ben’s take

I do this math for a living, and the honest version of it is a range so wide that the point estimate is a negotiation, not a fact. That is fine for investors, who are paid to take the risk. It is not fine when the valuation leaks out as evidence — when a reader hears "$1.8 billion longevity company" and assumes the money knows something about the biology. It does not. It knows the market is large and the founders are serious. The Phase 1 readout in August will be the first fact in the story.

Loree’s take

Phase 1 in Alzheimer's patients is a safety study, and the company is to be credited for choosing a disease with a diagnosis rather than selling "aging" to the healthy. What a patient should take from today is simple: a company's worth is not a treatment's evidence. When the trial reports, we will know whether the pill was tolerated. Whether it does anything is a question for a later year and a larger study.

Why it matters to a recovering optimizer. Valuations are the longevity industry's favorite proxy for progress, and they are a measure of belief, not of effect. The same multiplication that produces $1.8 billion for a drug company produces the $11 billion ring and the $2.5 billion blood panel — a big market, a confident story, a long horizon. None of those numbers has ever extended a life. Keep that in mind each time one is quoted at you as if it had.